Fujirebio showcases its LUMIPULSE® G series at Arab Health / Medlab 2016 and announces availability of the range in United Arab Emirates and the Nordic Countries
“The European immunoassay testing market has already received the LUMIPULSE G series very positively since the first introduction in 2011; our analyzers are today performing both specialized and routine testing in numerous laboratories across Italy, Spain, France, BENELUX and DACH.” said Christiaan De Wilde, CEO of Fujirebio Europe. “We are very excited to be opening this next chapter in the distribution of the LUMIPULSE G range outside our affiliate countries, through our long-lasting distribution partners in UAE and the Nordic Countries.”
Founded in 1950 in Japan Fujirebio has successfully been designing, manufacturing and marketing automated immunoassay testing solutions since 1991 and has for years been in a leading position on the Japanese immunoassay testing market.
The LUMIPULSE G1200 was launched by Fujirebio in Europe for the first time in 2011. The system has a robust and streamlined design, features a unique mono test cartridge concept and a true throughput of 120 tests per hour. It has a broad and constantly growing assay menu featuring both exclusive and routine markers for infectious diseases, oncology, thyroid, fertility and bone metabolism (non-exhaustive list), including the recently launched Lumipulse G HE4 and Lumipulse G B•R•A•H•M•S PCT assays.
The LUMIPULSE G600II, a more recent member in the LUMIPULSE G series of CLEIA analyzers, was first made available in Europe in 2014. The LUMIPULSE G600II is a compact and robust benchtop analyzer which uses the same unique mono test cartridge concept as the LUMIPULSE G1200, features a constant throughput of 60 tests per hour and uses largely the same broad and innovating menu as the LUMIPULSE G1200.
During the Arab Health / Medlab 2016 congress Fujirebio will also present its TENDIGO™, a small, state-of-the-art, and cost-efficient instrument designed specifically for laboratories who seek to perform low throughput automation of Fujirebio’s gold standard strip-based INNO-LIA and INNO-LiPA assay portfolios. The instrument also allows for automated testing of other blot strips (open protocols).
The products mentioned in this press release might not be available in the USA and in Canada. Please contact us for further information.
About Fujirebio
Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics (IVD) testing solutions. Founded more than 60 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostics solutions.
The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone metabolism.
Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and counts more than 1.300 employees working in Asia, Europe and America, including subsidiaries. For more information about Fujirebio please visit www.fujirebio.com/english or www.fujirebio-europe.com.
